Tadalafil
| Tadalafil | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 389.40 g/mol [1] |
| Melting point | 301-302 °C [1] |
| Solubility | Practically insoluble in water [1] |
| Predicted LogP | 2.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H19N3O4 |
| IUPAC name | (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione |
| SMILES | CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36 |
| InChI | InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1 |
| InChIKey | WOXKDUGGOYFFRN-IIBYNOLFSA-N |
| CAS number | 171596-29-5 |
| UNII | 742SXX0ICT |
| PubChem CID | 110635 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 30 minutes |
| Elimination half-life | 17.5 hours |
| Duration of action | ≤ 36 hours |
| Metabolism | Liver (predominantly CYP3A4) |
| Excretion | Feces (~61%), urine (~36%)[3] |
| Routes of administration | By mouth |
| Dosing[] |
|---|
| Oral [] | |
|---|---|
| Light | ≤ 12.5 mg(34x - 40.0%) |
| Common | 12.5 - 15 mg(13x - 15.3%) |
| Strong | 15 - 20 mg(34x - 40.0%) |
| Heavy | 20 mg |
| Extreme | 20 mg +(4x - 4.7%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Tadalafil (also known as Cialis, Ic351, Adcirca, Ic-351, Tadalafilo, Tadalafil mylan, Trans-tadalafil, Ic 351, Chewtadzy or Ly-450190) is a substance of the 3,4-methylenedioxyphenethylamine and β-carboline class.
Chemistry
Stereochemistry []
Tadalafil is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Tadalafil matches Lipinski's rule of five.Reagents
There are currently 9 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | purple / blue | |
| Mecke | purple / blue | |
| Mandelin | purple - brown | |
| Liebermann | dark brown | |
| Froehde | dark blue | |
| Robadope | no pink color change | |
| Simon's | no blue color change | |
| Hofmann | blue | |
| Zimmermann | no change / faint yellow |
Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- urologicals (G04)
- urologicals (G04B)
- drugs used in erectile dysfunction (G04BE)
- (G04BE08)
- tadalafil (G04BE08)
MeSH Classification
Mechanism of action []
Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP). cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection. In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction. Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED. Lastly, tadalafil is used to treat BPH. BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate. The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade. The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision. [1]
Interactions []
Medical side effects []
148 side effects listed on drug labels in SIDER 4.1 (tadalafil).
- Headache
- Nausea
- Respiratory tract infection
- Sinus congestion
- Pulmonary hypertension
- Dyspnoea
- Asthenia
- Fatigue
- Vomiting
- Oedema peripheral
- Oedema
- Constipation
- Cough
- Dyspepsia
- Gastroenteritis
- Menorrhagia
- Nasopharyngitis
- Uterine haemorrhage
- Viral diarrhoea
- Non-cardiac chest pain
- Menopausal symptoms
- Hot flush
- Therapeutic response unexpected
- Insomnia
- Musculoskeletal stiffness
- Back pain
- Flushing
- Influenza
- Upper respiratory tract infection
- Bronchitis
- Gastrooesophageal reflux disease
- Nasal congestion
- Pain in extremity
- Urinary tract infection
- Myalgia
- Musculoskeletal discomfort
- Arthralgia
- Diarrhoea
- Loose stools
- Abdominal pain
- Gastrointestinal pain
- Dizziness
- Syncope
- Hypertension
- Eye pain
- Conjunctival hyperaemia
- Angina pectoris
- Angina unstable
- Cardiovascular disorder
- Transient ischaemic attack
- Chest pain
- Dermatitis exfoliative
- Epistaxis
- Dermatitis
- Rash
- Hyperhidrosis
- Sweating
- Hypersensitivity
- Hypotension
- Myocardial infarction
- Acute coronary syndrome
- Palpitations
- Priapism
- Retinal artery occlusion
- Retinal vein occlusion
- Scotoma
- Convulsion
- Erythema multiforme
- Stevens-Johnson syndrome
- Cerebrovascular accident
- Shock
- Loss of consciousness
- Tachycardia
- Urticaria
- Sudden cardiac death
- Ventricular arrhythmia
- Migraine
- Transient global amnesia
- Vision blurred
- Face oedema
- Spontaneous penile erection
- Optic ischaemic neuropathy
- Arteritic anterior ischaemic optic neuropathy
- Erection increased
- Blindness
- Angioedema
- Mental disorder
- Bone disorder
- Breast disorder
- Neck pain
- Infection
- Conjunctivitis
- Connective tissue disorder
- Sudden hearing loss
- Dysphagia
- Oesophagitis
- Eye disorder
- Gastritis
- Gastrointestinal disorder
- Cardiac disorder
- Haematuria
- Haemorrhage
- Haemoglobin
- Hypoaesthesia
- Orthostatic hypotension
- Immune system disorder
- Infarction
- Mediastinal disorder
- Metrorrhagia
- Nervous system disorder
- Pain
- Paraesthesia
- Pharyngitis
- Pruritus
- Retinal vascular occlusion
- Rhinitis
- Muscle spasms
- Swelling
- Tinnitus
- Urethral disorder
- Urinary tract disorder
- Angiopathy
- Vertigo
- Dry mouth
- Sinus bradycardia
- Haematospermia
- Liver function test abnormal
- Skin disorder
- Abdominal discomfort
- Upset stomach
- Abdominal pain upper
- Abdominal pain lower
- Menometrorrhagia
- Amnesia
- Discomfort
- Haemorrhoidal haemorrhage
- Rectal haemorrhage
- Penile haemorrhage
- Lacrimation increased
- Infestation
- Limb discomfort
- Deafness
- Hearing impaired
- Renal failure
- Renal impairment
- Colour blindness acquired
- Somnolence
- Vaginal haemorrhage
Indications
- Benign prostatic hyperplasia
- Collagen-vascular disease
- Connective tissue disorder
- Diabetes mellitus
- Erectile dysfunction
- Hypertension
- Primary pulmonary hypertension
Subjective effects []
Legal status []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 110635, Tadalafil. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/110635
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tadalafil. UNII: 742SXX0ICT. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/742SXX0ICT
Cialis- tadalafil tablet, film coated. DailyMed. 12 June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcd8f8ab-81a2-4891-83db-24a0b0e25895
Cialis 10mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 26 April 2017. https://www.medicines.org.uk/emc/product/7431/smpc
Adcirca- tadalafil tablet. DailyMed. 23 June 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae
Cialis EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/cialis
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 12:48:12 |
| drugspro | ok | 2026-11-20 12:48:08 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 12:48:08 |
| gsrs | ok | 2026-11-20 12:48:09 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014958) | 2026-11-20 12:48:08 |
| kegg | ok | 2026-11-20 12:48:10 |
| pubchem | ok | 2026-11-20 12:48:08 |
| missing (no r/tripreports posts mention it) | 2026-11-20 12:48:08 | |
| sider | ok | 2026-11-20 12:48:09 |
| structure | ok | 2026-11-20 12:48:08 |
| wikipedia | ok | 2026-11-20 12:48:09 |